---
title: "Savara Q4 Net Income USD -32.236 Million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279039867.md"
datetime: "2026-03-13T12:05:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279039867.md)
  - [en](https://longbridge.com/en/news/279039867.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279039867.md)
---

# Savara Q4 Net Income USD -32.236 Million

Mar 13 (Reuters) - Savara Q4 operating expenses USD 33.419 million. \* Q4 income from operations USD -33.419 million \* Q4 EPS USD -0.13

### Related Stocks

- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)
- [BUZZ-Precision BioSciences up as hepatitis B gene‑editing trial expands in Europe](https://longbridge.com/en/news/282832865.md)
- [Revolution Medicines' experimental cancer pill helps improve survival in late-stage study](https://longbridge.com/en/news/282540793.md)
- [Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive](https://longbridge.com/en/news/282775123.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)